Emergence of institutional antithrombotic protocols for coronavirus 2019

INTRODUCTION The coronavirus disease 2019 (COVID‐19), first identified in December 2019 in Wuhan, China, is a major public health crisis with new infections increasing exponentially worldwide. 1 COVID‐19 is an acute infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SA...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Research and practice in thrombosis and haemostasis Ročník 4; číslo 4; s. 510 - 517
Hlavní autori:	Cohoon, Kevin P., Mahé, Guillaume, Tafur, Alfonso J., Spyropoulos, Alex C.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 01.05.2020 Elsevier Limited Wiley John Wiley and Sons Inc Elsevier
Predmet:	acute infectious disease anticoagulant Anticoagulants antiplatelet antithrombotic therapy Body mass index coronavirus Coronaviruses COVID-19 Cytokines deep vein thrombosis Disease prevention Enzymes Forum Heparan sulfate Hospitals Illnesses Infections Infectious diseases Influenza Laboratories Life Sciences Medical prognosis Mortality Pandemics Pneumonia pulmonary embolism Pulmonary embolisms pulmonary infection SARS‐CoV‐2 Severe acute respiratory syndrome coronavirus 2 Thromboembolism Thrombosis United States > US pulmonary infection deep vein thrombosis COVID‐19 SARS‐CoV‐2 acute infectious disease coronavirus anticoagulant antithrombotic therapy pulmonary embolism antiplatelet
ISSN:	2475-0379, 2475-0379
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!